SS&H Financial Advisors Inc. Sells 1,150 Shares of Amgen Inc. $AMGN

SS&H Financial Advisors Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,928 shares of the medical research company’s stock after selling 1,150 shares during the quarter. Amgen makes up approximately 1.1% of SS&H Financial Advisors Inc.’s investment portfolio, making the stock its 22nd biggest position. SS&H Financial Advisors Inc.’s holdings in Amgen were worth $3,330,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in Amgen by 5.5% during the first quarter. Golden State Wealth Management LLC now owns 1,933 shares of the medical research company’s stock valued at $602,000 after purchasing an additional 101 shares in the last quarter. Calamos Wealth Management LLC boosted its position in shares of Amgen by 4.8% in the first quarter. Calamos Wealth Management LLC now owns 2,578 shares of the medical research company’s stock worth $803,000 after purchasing an additional 119 shares during the period. Silver Oak Securities Incorporated increased its stake in shares of Amgen by 4.1% in the first quarter. Silver Oak Securities Incorporated now owns 1,761 shares of the medical research company’s stock worth $541,000 after purchasing an additional 70 shares in the last quarter. Finally, 44 Wealth Management LLC increased its stake in shares of Amgen by 28.0% in the first quarter. 44 Wealth Management LLC now owns 1,197 shares of the medical research company’s stock worth $373,000 after purchasing an additional 262 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $298.43 on Friday. The company has a market cap of $160.66 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 2.61 and a beta of 0.49. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88. The stock’s 50 day simple moving average is $287.75 and its two-hundred day simple moving average is $287.46. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the firm posted $4.97 earnings per share. Amgen’s revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.76% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on AMGN shares. Piper Sandler lifted their target price on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Raymond James Financial initiated coverage on Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. UBS Group dropped their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 27th. Finally, Citigroup boosted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $300.94.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.